A double-blind, randomized, controlled study with subjects who are not taking concomitant anti-Parkinson’s medication potentially affecting cognitive function may be necessary in the future in order to clarify the effect that RLAI has on cognitive dysfunction. Conclusion This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching schizophrenia patients from oral risperidone to RLAI compared with a control group that continued to receive oral risperidone. Patients with RLAI needed less

biperiden, Inhibitors,research,lifescience,medical even though they had similar risperidone-equivalent daily dosages as the group with oral risperidone. The results of this study suggested that switching from oral risperidone to RLAI may affect motor processing function and attention improvement efficacy by allowing the dosage of anti-Parkinson’s medication to be reduced. Footnotes This research received no specific grant from any funding agency in the public, commercial,

Inhibitors,research,lifescience,medical or not-for-profit sectors. The authors declare no conflicts of interest in preparing this article.
Background: Amisulpride is a second-generation antipsychotic which has been proved to be effective in the control of both positive and negative symptoms of schizophrenia. In this study we aimed to Inhibitors,research,lifescience,medical determine metabolic, endocrinologic and cardiac effects of amisulpride commonly used in Inhibitors,research,lifescience,medical our clinical practice. Methods: A total of 18 patients (11 males, 7 females) diagnosed with schizophrenia received amisulpride at the dosage of

800 mg/day and were followed up for 24 weeks. Positive and negative psychotic symptoms, extrapyramidal and sexual side effects, metabolic, endocrinologic and cardiac Inhibitors,research,lifescience,medical parameters were evaluated at regular intervals. Results: Significant improvement in both positive and negative symptoms was observed in patients starting from the second week of treatment. Prolactin levels increased significantly both in men and women starting from the measurement on day 4. Prolactin elevation was significantly higher in women than in men. Increase in total cholesterol level became significant at week 24. No other significant difference was observed between weeks 1 and 24 regarding the other parameters. Conclusions: The clinical data from the Ulixertinib ic50 present study supports the fact that amisulpride is an effective and safe antipsychotic drug, but elevates prolactin levels in both sexes. Keywords: amisulpride, efficacy, hormones, hyperprolactinemia, metabolic control, QT interval, side effects Introduction Schizophrenia is a chronic and disabling disorder with a lifetime prevalence of approximately 1% [American Psychiatric Association, 1994]. Antipsychotic treatment remains mandatory for patients with an Wortmannin established diagnosis of schizophrenia [Mortimer, 2003].